In BRAFV600+ MM, short-term treatment is not associated to a full pDC recovery; however, TLR-9 agonists as adjuvant remain a valid therapeutic strategy for a proficient pDC activation. The gene discussed is TLR9; the disease is Miyoshi myopathy.